The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017 Nov 13 [Epub]
E Gallardo, M J Méndez-Vidal, J L Pérez-Gracia, J M Sepúlveda-Sánchez, M Campayo, I Chirivella-González, X García-Del-Muro, A González-Del-Alba, E Grande, C Suárez
Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Parc Taulí, 1, 08208, Sabadell, Spain., Medical Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Córdoba, Spain., Medical Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain., Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, Spain., Medical Oncology Department, Hospital Clínico, Universidad de Valencia, Valencia, Spain., Medical Oncology Department, Institut Catala d'Oncologia, Idibell, Universitat de Barcelona, Barcelona, L'Hospitalet de Llobregat, Spain., Oncology Department, Hospital Universitario Son Espases, Palma De Mallorca, Spain., Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. .